Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $72.2 million.

  • Entrada Therapeutics' Total Liabilities fell 4537.58% to $72.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year decrease of 4537.58%. This contributed to the annual value of $97.6 million for FY2024, which is 5695.36% down from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Total Liabilities is $72.2 million, which was down 4537.58% from $69.3 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Total Liabilities peaked at $287.1 million during Q2 2023, and registered a low of $39.3 million during Q1 2022.
  • Over the past 4 years, Entrada Therapeutics' median Total Liabilities value was $97.6 million (recorded in 2024), while the average stood at $132.8 million.
  • Per our database at Business Quant, Entrada Therapeutics' Total Liabilities soared by 61988.31% in 2023 and then plummeted by 7133.52% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Total Liabilities stood at $39.5 million in 2022, then surged by 474.23% to $226.8 million in 2023, then tumbled by 56.95% to $97.6 million in 2024, then decreased by 26.08% to $72.2 million in 2025.
  • Its Total Liabilities was $72.2 million in Q3 2025, compared to $69.3 million in Q2 2025 and $69.2 million in Q1 2025.